Published in J Acquir Immune Defic Syndr on August 01, 2009
Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol (2013) 2.64
Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS (2014) 1.66
HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis (2012) 1.49
Overdose Education and Naloxone for Patients Prescribed Opioids in Primary Care: A Qualitative Study of Primary Care Staff. J Gen Intern Med (2015) 1.49
Disparities among US states in HIV-related mortality in persons with HIV infection, 2001-2007. AIDS (2012) 1.27
Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr (2011) 1.22
Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. AIDS (2012) 1.21
Excess mortality among HIV-infected patients diagnosed with substance use dependence or abuse receiving care in a fully integrated medical care program. Alcohol Clin Exp Res (2010) 1.13
Estimating the potential pool of HIV-infected deceased organ donors in the United States. Am J Transplant (2011) 1.07
Alcohol consumption among HIV-infected women: impact on time to antiretroviral therapy and survival. J Womens Health (Larchmt) (2011) 1.07
Prevalence and patient awareness of medical comorbidities in an urban AIDS clinic. AIDS Patient Care STDS (2010) 1.05
Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med (2013) 1.05
Mortality after diagnosis of psychiatric disorders and co-occurring substance use disorders among HIV-infected patients. AIDS Patient Care STDS (2010) 1.04
Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. Am J Physiol Endocrinol Metab (2010) 1.03
Pre-existing albuminuria predicts AIDS and non-AIDS mortality in women initiating antiretroviral therapy. Antivir Ther (2011) 1.01
Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. AIDS (2013) 0.92
Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus. J Infect Dis (2013) 0.92
Urinary biomarkers of kidney injury are associated with all-cause mortality in the Women's Interagency HIV Study (WIHS). HIV Med (2013) 0.92
Tuberculosis and HIV co-infection, California, USA, 1993–2008. Emerg Infect Dis (2013) 0.89
Epidemiology of coronary heart disease in patients with human immunodeficiency virus. Rev Cardiovasc Med (2014) 0.87
Association of urine α1-microglobulin with kidney function decline and mortality in HIV-infected women. Clin J Am Soc Nephrol (2014) 0.85
Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN Gastroenterol (2011) 0.81
Gender-Related Risk Factors Improve Mortality Predictive Ability of VACS Index Among HIV-Infected Women. J Acquir Immune Defic Syndr (2015) 0.81
Comparison of Rates of Death Having any Death-Certificate Mention of Heart, Kidney, or Liver Disease Among Persons Diagnosed with HIV Infection with those in the General US Population, 2009-2011. Open AIDS J (2015) 0.81
Fasting Triglyceride Concentrations are Associated with Early Mortality Following Antiretroviral Therapy in Zambia. N Am J Med Sci (Boston) (2010) 0.81
Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus. Vasc Health Risk Manag (2015) 0.81
Switching antiretroviral therapy to minimize metabolic complications. HIV Ther (2010) 0.80
Liver transplantation trends in the HIV population. Dig Dis Sci (2011) 0.79
Psychostimulant-related deaths among former inmates. J Addict Med (2012) 0.79
Relationship between Body Mass Index and Mortality in HIV-Infected HAART Users in the Women's Interagency HIV Study. PLoS One (2015) 0.79
RYR3 gene variants in subclinical atherosclerosis among HIV-infected women in the Women's Interagency HIV Study (WIHS). Atherosclerosis (2014) 0.78
Activation of persons living with HIV for treatment, the great study. BMC Public Health (2015) 0.78
Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection. J Infect Dis (2012) 0.78
Use of urine biomarker-derived clusters to predict the risk of chronic kidney disease and all-cause mortality in HIV-infected women. Nephrol Dial Transplant (2016) 0.77
Factors associated with treatment initiation for psychiatric and substance use disorders among persons with HIV. Psychiatr Serv (2013) 0.77
Obesity is associated with race/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults. AIDS Res Hum Retroviruses (2015) 0.77
Systemic cytokine and interferon responsiveness Patterns in HIV and HCV mono and co-infections. J Interferon Cytokine Res (2014) 0.76
Chronic depressive symptoms and Framingham coronary risk in HIV-infected and HIV-uninfected women. AIDS Care (2011) 0.76
Food insecurity with hunger is associated with obesity among HIV-infected and at risk women in Bronx, NY. PLoS One (2014) 0.76
Effects of Antiretroviral Therapy and Depressive Symptoms on All-Cause Mortality Among HIV-Infected Women. Am J Epidemiol (2017) 0.75
Relationship between ever reporting depressive symptoms and all-cause mortality in a cohort of HIV-infected adults in routine care. AIDS (2017) 0.75
Association of markers of hemostasis with death in HIV-infected women. J Acquir Immune Defic Syndr (2014) 0.75
Ideal Cardiovascular Health and Carotid Atherosclerosis in a Mixed Cohort of HIV-Infected and Uninfected Ugandans. AIDS Res Hum Retroviruses (2016) 0.75
Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study. Medicine (Baltimore) (2016) 0.75
Trajectory analyses of virologic outcomes reflecting community-based HIV treatment in Washington DC 1994-2012. BMC Public Health (2015) 0.75
HIV positive youth who are perinatally infected have impaired endothelial function. AIDS (2017) 0.75
Macrophage Activation and the Tumor Necrosis Factor Cascade in Hepatitis C Disease Progression Among HIV-Infected Women Participating in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2017) 0.75
Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation. Curr HIV/AIDS Rep (2017) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology (1998) 12.32
Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr (2006) 12.07
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord (1994) 6.61
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med (2006) 5.49
Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol (2004) 3.99
Domestic violence and childhood sexual abuse in HIV-infected women and women at risk for HIV. Am J Public Health (2000) 3.37
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (2006) 3.23
Accuracy of death certificate completion: the need for formalized physician training. JAMA (1996) 3.09
Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am J Epidemiol (2001) 2.77
Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health (2004) 2.66
Trends in mortality statistics in England and Wales with particular reference to AIDS from 1984 to April 1987. Br Med J (Clin Res Ed) (1988) 2.61
Depressive symptoms as predictors of medical outcomes in HIV infection. Multicenter AIDS Cohort Study. JAMA (1993) 2.39
Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr (2002) 2.30
Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health (2004) 2.18
Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 2.15
A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr (2005) 2.15
Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med (2005) 2.12
Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med (2002) 2.11
All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS (2004) 1.91
Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS (2001) 1.88
Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort. Clin Infect Dis (2003) 1.70
Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. Am J Public Health (2007) 1.68
Depressive symptoms, major depression, and generalized anxiety: a comparison of self-reports on CES-D and results from diagnostic interviews. Psychiatry Res (1985) 1.66
Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis (2006) 1.61
The effect of HIV infection on overdose mortality. AIDS (2005) 1.58
Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr (2000) 1.42
Antidepressant treatment and health services utilization among HIV-infected medicaid patients diagnosed with depression. J Gen Intern Med (2000) 1.40
When obesity is desirable: a longitudinal study of the Miami HIV-1-infected drug abusers (MIDAS) cohort. J Acquir Immune Defic Syndr (2000) 1.39
Obesity and immune cell counts in women. Metabolism (2007) 1.31
Impact of HIV infection on mortality and accuracy of AIDS reporting on death certificates. Am J Public Health (1992) 1.27
Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the Southeastern United States. South Med J (2007) 1.04
Alterations in T-cell subset frequency in peripheral blood in obesity. Obes Surg (2005) 1.04
Differential diffusion of HIV technologies by gender: the case of highly active antiretroviral therapy. AIDS Patient Care STDS (2007) 0.95
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol (2003) 5.81
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health (2008) 5.32
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol (2002) 4.20
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (2008) 3.66
Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis (2004) 3.17
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med (2004) 3.05
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis (2004) 2.89
Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int (2002) 2.83
Rapid HIV-1 testing during labor: a multicenter study. JAMA (2004) 2.81
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol (2005) 2.69
Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis (2007) 2.67
Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health (2004) 2.66
Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis (2004) 2.66
Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol (2003) 2.60
Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis (2004) 2.59
Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis (2007) 2.55
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev (2005) 2.45
Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS (2005) 2.42
Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer (2007) 2.37
Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A (2004) 2.30
Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr (2002) 2.30
Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS (2008) 2.28
Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter? Clin Infect Dis (2004) 2.23
Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst (2004) 2.23
Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol (2005) 2.20
Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health (2006) 2.19
Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health (2004) 2.18
Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health (2002) 2.15
Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.11
Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med (2002) 2.11
Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS (2007) 2.10
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis (2005) 2.04
Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Stat Med (2004) 2.04
Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS (2005) 2.03
Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol (2007) 2.00
Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev (2010) 2.00
Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr (2003) 1.95
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS (2011) 1.94
Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS (2004) 1.94
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Cancer risk among participants in the women's interagency HIV study. J Acquir Immune Defic Syndr (2004) 1.90
Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr (2010) 1.87
Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA (2005) 1.86
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis (2010) 1.85
Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One (2011) 1.80
Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr (2003) 1.78
Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med (2002) 1.75
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A (2003) 1.71
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis (2011) 1.70
Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS (2009) 1.68
Within-individual stability of obesity-related biomarkers among women. Cancer Epidemiol Biomarkers Prev (2007) 1.67
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr (2007) 1.66
Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis (2006) 1.61
Utility of Amsel criteria, Nugent score, and quantitative PCR for Gardnerella vaginalis, Mycoplasma hominis, and Lactobacillus spp. for diagnosis of bacterial vaginosis in human immunodeficiency virus-infected women. J Clin Microbiol (2005) 1.60
Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis (2002) 1.59
Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2004) 1.58
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.57
Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination. J Virol (2005) 1.53
Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res (2004) 1.50
Comparison of standard and immune-enhancing oral formulas in asymptomatic HIV-infected persons: a multicenter randomized controlled clinical trial. JPEN J Parenter Enteral Nutr (2002) 1.49
Self-administered vaginal swabs are a feasible alternative to physician-assisted cervical swabs for sexually transmitted infection screening in the emergency department. Acad Emerg Med (2009) 1.48
Lung cancer incidence and survival among HIV-infected and uninfected women and men. AIDS (2015) 1.47